1.2(top 17%)
Impact Factor
1.3(top 17%)
extended IF
117(top 3%)
H-Index
4K
authors
10.8K
papers
105.7K
citations
5.5K
citing journals
51K
citing authors

Most Cited Articles of European Neuropsychopharmacology

TitleYearCitations
The size and burden of mental disorders and other disorders of the brain in Europe 201020112.2K
Exploring the brain network: a review on resting-state fMRI functional connectivity20101.9K
Cost of disorders of the brain in Europe 20102011987
Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies2005935
Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism2002444
Size of burden of schizophrenia and psychotic disorders2005406
Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial2003364
Inflammation and clinical response to treatment in depression: A meta-analysis2015360
Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses2012360
Prevalence and incidence of Parkinson's disease in Europe2005355
Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action2010338
The impact of stress on addiction2003304
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)1997295
Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence2011293
Treatment resistant depression: methodological overview and operational criteria1999272
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)1997271
The hippocampal-prefrontal pathway: the weak link in psychiatric disorders?2013267
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD2009267
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy1998262
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy2012238
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence2013231
Size and burden of social phobia in Europe2005227
Prevalence and burden of bipolar disorders in European countries2005226
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder2006226
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis2001224